CARDIFF ONCOLOGY, INC. Payments of Stock Issuance Costs
CARDIFF ONCOLOGY, INC. (CRDF) reported Payments of Stock Issuance Costs of $64.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2026-08-11
- CARDIFF ONCOLOGY, INC. payments of stock issuance costs for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- CARDIFF ONCOLOGY, INC. payments of stock issuance costs for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- CARDIFF ONCOLOGY, INC. payments of stock issuance costs for the quarter ending 2024-12-31 was $2.80M.
- CARDIFF ONCOLOGY, INC. payments of stock issuance costs for the quarter ending 2024-09-30 was $285.00K.
- CARDIFF ONCOLOGY, INC. payments of stock issuance costs for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- CARDIFF ONCOLOGY, INC. payments of stock issuance costs for fiscal 2024 was $3.29M.
- CARDIFF ONCOLOGY, INC. payments of stock issuance costs for fiscal 2023 was $0.00.
- CARDIFF ONCOLOGY, INC. payments of stock issuance costs for fiscal 2021 was $800.00K.
| Period end | Payments of Stock Issuance Costs | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 6 month as first filed | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 9 month as first filed | Payments of Stock Issuance Costs 12 month | Payments of Stock Issuance Costs 152 month | Payments of Stock Issuance Costs 155 month | Payments of Stock Issuance Costs 158 month | Payments of Stock Issuance Costs 161 month | Payments of Stock Issuance Costs 164 month | Payments of Stock Issuance Costs 167 month | Payments of Stock Issuance Costs 170 month | Payments of Stock Issuance Costs 173 month | Payments of Stock Issuance Costs 176 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $64.00K 10-Q · filed 2026-08-11 | |||||||||||||||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $0.00 derived: sum of 2 quarters · filed 2026-02-24 | $0.00 10-K · filed 2026-02-24 | |||||||||||||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | ||||||||||||||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-11 | |||||||||||||||
| 2024-12-31 | $2.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $3.09M derived: sum of 2 quarters · filed 2026-02-24 | $3.29M derived: sum of 3 quarters · filed 2026-02-24 | $3.29M 10-K · filed 2026-02-24 | ||||||||||||
| 2024-09-30 | $285.00K 10-Q · filed 2025-11-06 | $482.00K derived: sum of 2 quarters · filed 2025-11-06 | $482.00K 10-Q · filed 2025-11-06 | |||||||||||||
| 2024-06-30 | $197.00K 10-Q · filed 2025-11-06 | $197.00K 10-Q · filed 2025-07-29 | ||||||||||||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $0.00 derived: sum of 2 quarters · filed 2025-02-27 | $0.00 10-K · filed 2025-02-27 | |||||||||||||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | ||||||||||||||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-08 | |||||||||||||||
| 2022-09-30 | -$776.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $24.00K derived: sum of 2 quarters · filed 2022-11-03 | $0.00 10-Q · filed 2022-11-03 | |||||||||||||
| 2022-06-30 | $800.00K 10-Q · filed 2022-08-04 | $776.00K 10-Q · filed 2022-08-04 | ||||||||||||||
| 2021-12-31 | $24.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $24.00K derived: sum of 2 quarters · filed 2023-03-02 | $824.00K derived: sum of 3 quarters · filed 2023-03-02 | $800.00K 10-K · filed 2023-03-02 | ||||||||||||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $800.00K derived: sum of 2 quarters · filed 2022-11-03 | $776.00K 10-Q · filed 2022-11-03 | |||||||||||||
| 2021-06-30 | $800.00K 10-Q · filed 2022-11-03 | $776.00K 10-Q · filed 2021-08-05 | ||||||||||||||
| 2021-03-31 | $0.00 10-Q · filed 2021-05-06 | |||||||||||||||
| 2020-09-30 | $541.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $0.00 derived: sum of 2 quarters · filed 2021-11-04 | $634.00K 10-Q · filed 2021-11-04 | $633.81K 10-Q · filed 2020-11-05 | ||||||||||||
| 2020-06-30 | -$541.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $93.00K 10-Q · filed 2021-08-05 | $92.65K 10-Q · filed 2020-08-11 | |||||||||||||
| 2020-03-31 | $634.00K 10-Q · filed 2021-05-06 | |||||||||||||||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $97.26K 10-Q · filed 2020-11-05 | ||||||||||||||
| 2019-06-30 | $97.26K 10-Q · filed 2020-08-11 | |||||||||||||||
| 2018-12-31 | $1.83M 10-K · filed 2019-03-06 | |||||||||||||||
| 2018-06-12 | $1.80M 10-K · filed 2020-02-27 | |||||||||||||||
| 2017-12-31 | $866.04K 10-K · filed 2019-03-06 | |||||||||||||||
| 2016-12-31 | $79.39K 10-K · filed 2018-02-26 | |||||||||||||||
| 2014-03-31 | $277.10K 10-Q · filed 2014-05-12 | |||||||||||||||
| 2013-12-31 | $277.10K 10-K · filed 2014-03-17 | |||||||||||||||
| 2013-09-30 | $277.10K 10-Q · filed 2013-11-14 | |||||||||||||||
| 2013-06-30 | $277.10K 10-Q · filed 2013-08-14 | |||||||||||||||
| 2013-03-31 | $277.10K 10-Q · filed 2013-05-14 | |||||||||||||||
| 2012-12-31 | $277.10K 10-K · filed 2013-04-01 | |||||||||||||||
| 2012-09-30 | $277.10K 10-Q · filed 2012-11-14 | |||||||||||||||
| 2012-06-30 | $277.10K 10-Q · filed 2012-08-14 | |||||||||||||||
| 2012-03-31 | $277.10K 10-Q · filed 2012-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |